Resultados de Búsqueda

Evidencias COVID-19

Oxford COVID-19 Evidence Service

Smoking is a known risk factor for acute respiratory infections in general and for a variety of comorbidities, many of which are associated with poorer COVID-19 outcomes. It is also a risk factor for people who smoke as well as for those around them. Data is still emerging on COVID-19, with conflicting evidence on whether people who smoke have a higher or lower risk of COVID-19.

Evidencias COVID-19

Oxford COVID-19 Evidence Service

We found no clinical evidence on vitamin D in COVID-19. There was no evidence related to vitamin D deficiency predisposing to COVID-19, nor were there studies of supplementation for preventing or treating COVID-19. There is some evidence that daily vitamin D3 supplementation over weeks to months may prevent other acute respiratory infections, particularly in people with low or very low vitamin D status. This evidence has limitations, including heterogeneity in study populations, interventions, ...

Evidencias COVID-19

Oxford COVID-19 Evidence Service

Patients with severe COVID-19 can develop cytokine release syndrome (“cytokine storm”) and are reported to have high circulating IL-6 concentrations. Tocilizumab is a recombinant humanized anti-human IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R). Tocilizumab has been used to treat cytokine release syndrome due to CAR-T cell therapy. However, its use in COVID-19 is experimental. It should not be used except in the context of clinical trials to establish whether ...

Evidencias COVID-19

Oxford COVID-19 Evidence Service

There is a small body of evidence to suggest that activities delivered at home by family carers may have some positive effects on cognition (and mood) All activities should be tailored to meet the individual needs and preferences of people with dementia, in order to ensure all activities are engaging and enjoyable.

Evidencias COVID-19

Oxford COVID-19 Evidence Service

Oxygen in many LMIC settings has limited availability. Even when available health care facilities may have to be selective in its use due to limited supply. Its use may have substantial cost implications for the health care facility and for the patient and their relatives. There is no existing research evidence involving patients with COVID-19 to directly inform the use of oxygen therapy in the management of breathlessness for dying patients. For patients with COVID-19, there is no evidence of ...